MYC and medulloblastoma: Similarly, in the context of MYC-amplified medulloblastoma, the de novo pyrimidine biosynthesis pathway and DHODH emerged as specific vulnerabilities of these cancers, and in these tumors DHODH loss resulted in MYC degradation and pyrimidine deprivation-induced cell-cycle arrest and apoptosis induction.73